{"analyses":[{"ciLowerLimit":"0.5023","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.8605","estimateComment":"Hazard Ratio based on stratified Cox proportional hazards model with stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0021","pValueComment":"Stratified Log-rank p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.6575","statisticalComment":"p value based on log-rank stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by IXRS","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"32.7","upperLimit":"NA","value":"39.2"},{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"21.0","upperLimit":"NA","value":"26.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"406"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received T-DXd as a sterile intravenous (IV) solution at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), who received investigator's choice treatment, Trastuzumab/Capecitabine or Lapatinib/Capecitabine.","id":"OG001","title":"Treatment of Investigator's/Physician's Choice (TPC)"}],"paramType":"MEDIAN","populationDescription":"Overall survival (OS) was assessed in the Full Analysis Set at data cut-off date of 30 Jun 2022.","reportingStatus":"POSTED","timeFrame":"Baseline up to 46 months postdose","title":"Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine","type":"SECONDARY","unitOfMeasure":"months"}